The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodics are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
ANGIOTENSIN RECEPTOR AUTOANTIBODIES AS BIOMARKER FOR EFFECTED USAGE OF ANGIOTENSIN RECEPTOR BLOCKERS